Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) variants poses major threats in increasing infectivity, transmission, mortality of Coronavirus Disease 2019 (Covid-19). Additionally, SARS CoV-2 variants resist antibody neutralizations or may abolish vaccine efficacies. Researches to develop economical and fast methods will support the developing or poor countries to challenge the Covid-19 pandemic via tracking common mutations that may help to deploy the vaccination programs and control the virus. Current study has developed a novel low-cost rapid technique, exploiting real time PCR probes and conventional PCR specific primers, to identify N501Y mutation, which was independently emerged in the UK, South African and Brazilian variants. Currently, these variants tend to spread to all over the world and seem to be more infectious, transmissible and fatal. This study helps tracking the N501Y mutation for understanding its clinical and epidemiological characteristics, in those countries where sequencing facilities are lacking or expensive. Further study should focus on other common mutations in the variants of concerns of SARS CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funds were provided for this research
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Consent forms were filled by the participants and the study was approved by an ethical committee at the Department of Biology, University of Garmian that follow the rules adhered to the Declaration of Helsinki for human and animal research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
). Two mutants and 4 wildtypes PCR products, amplified by conventional PCR amplifying 748 bp in the spike protein at the region of variants of concerns (Figure 3C), were confirmed using Sanger sequencings and the GenBanks (MW897351, MW897352, MW897353, MW897354, MW897355, and MW897356) were released to NCBI data base.
https://www.ncbi.nlm.nih.gov/nuccore/MW897351
https://www.ncbi.nlm.nih.gov/nuccore/MW897352
https://www.ncbi.nlm.nih.gov/nuccore/MW897353
https://www.ncbi.nlm.nih.gov/nuccore/MW897354
